{"product_id":"myriad-bcg-matrix","title":"Myriad Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Myriad BCG Matrix preview highlights portfolio dynamics—which platforms are scaling fast, which generate steady cash, and which may need divestment—framing strategic choices at a glance. This snapshot shows growth-share relationships and where managerial focus should shift to maximize ROI. The full BCG Matrix delivers quadrant-by-quadrant placements, data-driven recommendations, editable Word and Excel files, and tactical next steps tailored to Myriad’s market realities. Purchase the complete report for an actionable roadmap to prioritize investments and optimize product performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneSight Pharmacogenomics Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of Q3 2025 GeneSight (Myriad Genetics) leads psychotropic pharmacogenomics with ~42% market share and ~30% CAGR from 2021–2025, making it Myriad’s Star: high growth, high share.\u003c\/p\u003e\n\u003cp\u003eRising mental health screening and payer coverage lift revenue—GeneSight drove ~ $185M revenue in FY2024 and is projected \u0026gt;$240M in 2025—requiring sustained marketing spend to defend leadership.\u003c\/p\u003e\n\u003cp\u003eIt embodies personalized psychiatry adoption, capturing share while consuming cash for growth and commercial expansion; maintain investment to protect a clear first-mover advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyRisk Hereditary Cancer Suite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyRisk Hereditary Cancer Suite remains Myriad Genetics’ star in oncology, offering multi-gene panels covering increased risk for eight cancers and driving ~35% diagnostic share in hereditary testing by 2024, up from 22% in 2018.\u003c\/p\u003e\n\u003cp\u003eShift from single-gene to broad panels captured expanding market; hereditary oncology testing market projected CAGR 9% to reach $4.2B by 2026, with MyRisk core to Myriad’s $850M diagnostics revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003eOngoing RiskScore and polygenic updates (latest 2024 algorithm release improved AUC by 0.04) keep MyRisk competitive in a high-growth clinical segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecise Tumor Molecular Profiling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecise Tumor Molecular Profiling is a Star: a high-growth genomic profiling service for solid tumors targeting the $18B global precision oncology market (2025 estimate) with projected CAGR ~12% to 2030; it delivers actionable therapy-selection reports used by oncologists, shortening time-to-treatment by ~15 days in published cohorts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Women's Health Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced Women's Health Screening drives double-digit revenue growth for Myriad, with prenatal and hereditary cancer tests growing ~18% YoY and representing roughly $420M of 2025 revenue, keeping it a market leader in a \u0026gt;15% CAGR segment.\u003c\/p\u003e\n\u003cp\u003eMyriad’s dedicated sales force and 12,000 clinician relationships sustain \u0026gt;40% market share in women’s genetic tests, and integrated risk tools lift test-to-treatment conversion by ~22%, creating a durable competitive moat.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18% YoY growth; $420M 2025 revenue\u003c\/li\u003e\n\u003cli\u003e~40% market share in women's genetics\u003c\/li\u003e\n\u003cli\u003e12,000 clinician ties; dedicated sales force\u003c\/li\u003e\n\u003cli\u003eRisk tools increase conversion ~22%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData-Driven Clinical Decision Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad's proprietary database and software that interpret complex genetic variants are a Star in health informatics, driving 25–30% CAGR in clinical genomics services and supporting \u0026gt;1.2 million variant interpretations in 2025.\u003c\/p\u003e\n\u003cp\u003eAs genomic data volumes double ~every 18 months, definitive clinical classifications are high-growth, high-margin services; R\u0026amp;D spend of ~$120M in 2024 preserved a 15–20% accuracy edge.\u003c\/p\u003e\n\u003cp\u003eThis unit underpins the diagnostic portfolio, acting as essential infrastructure and enabling cross-sell across 60+ tests and payer contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary DB: \u0026gt;1.2M variants (2025)\u003c\/li\u003e\n\u003cli\u003eMarket growth: 25–30% CAGR\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D: ~$120M (2024)\u003c\/li\u003e\n\u003cli\u003eCoverage: supports 60+ tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Diagnostics Powerhouse: GeneSight, MyRisk, Tumor Profiling \u0026amp; Informatics Surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: GeneSight (42% share; ~$240M est. 2025; ~30% CAGR 2021–25), MyRisk (35% hereditary share; core to ~$850M diagnostics FY2024; market CAGR 9% to $4.2B by 2026), Tumor Profiling (~$18B market 2025; ~12% CAGR), Women's Health (~$420M 2025; ~18% YoY), Informatics (\u0026gt;1.2M variants 2025; 25–30% CAGR).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eKey\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight\u003c\/td\u003e\n\u003ctd\u003eShare\/CAGR\u003c\/td\u003e\n\u003ctd\u003e42%\/~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyRisk\u003c\/td\u003e\n\u003ctd\u003eShare\/Revenue\u003c\/td\u003e\n\u003ctd\u003e35%\/~$850M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Myriad’s units with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Myriad BCG Matrix placing each business unit in a clear quadrant for quick strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRACAnalysis CDx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRACAnalysis CDx, pioneer in BRCA1\/2 testing since 1996, sits in a mature market with ~40% U.S. market share and steady annual volume (~120k tests in 2024), yielding ~$150M revenue and strong operating cash flow; marketing spend under 5% of sales compared with 20% for new assays.\u003c\/p\u003e\n\u003cp\u003eAs primary internal R\u0026amp;D funder, it contributed ~$50M to Myriad R\u0026amp;D in 2024, supporting 12 clinical programs; its low churn and pricing power sustain margins near 45%.\u003c\/p\u003e\n\u003cp\u003eIt remains the gold standard companion diagnostic for select PARP inhibitor therapies—used in ~60% of eligible oncology prescriptions—anchoring long-term profitability and payer coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProlaris Prostate Cancer Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProlaris, Myriad Genetics’ prostate cancer prognostic test, holds a strong share in the mature prostate prognosis market, used in ~30–35% of eligible cases in the US as of 2024 and cited in \u0026gt;250 peer-reviewed studies for tumor aggressiveness.\u003c\/p\u003e\n\u003cp\u003eWith stable reimbursement (Medicare local coverage plus major private payers) and FY2024 oncology revenue contribution estimated at ~$120M, Prolaris delivers predictable margins.\u003c\/p\u003e\n\u003cp\u003eIt needs minimal capex or R\u0026amp;D now, letting Myriad allocate cash flow to high-growth areas like hereditary oncology and companion diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEndoPredict Breast Cancer Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEndoPredict, Myriad's second-generation breast cancer recurrence gene expression test, holds a stable global clinician adoption with ~35% market share in hormone-receptor positive early-stage cases as of 2025, delivering ~$110M annual revenue and \u0026gt;60% gross margins through integrated lab workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Hereditary Cancer Testing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCore hereditary cancer testing services generate steady, high-volume revenue—Myriad Genetics reported hereditary testing net revenue of $493M in FY2024, driven by legacy panels across oncology, cardiology, and OB\/GYN.\u003c\/p\u003e\n\u003cp\u003eThese services exploit economies of scale and entrenched payer and health system contracts, lowering per-test cost and preserving ~20–25% gross margins, sustaining free cash flow for debt servicing and R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eOperational efficiency and repeat referrals free up liquidity to fund AI diagnostic pilots and genomic platform upgrades without raising equity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 hereditary testing revenue: $493M\u003c\/li\u003e\n\u003cli\u003eEstimated gross margin: 20–25%\u003c\/li\u003e\n\u003cli\u003ePrimary customers: hospitals, oncology clinics, payers\u003c\/li\u003e\n\u003cli\u003eCash supports debt service and tech investments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMyriad’s centralized laboratory operations process over 3 million tests annually (2024), achieving margin expansion with operating margins near 25% and per-test costs falling 12% since 2021; they hold a leading share (\u0026gt;30%) in US molecular diagnostic processing, so require low incremental capital to sustain throughput.\u003c\/p\u003e\n\u003cp\u003eThe strong free cash flow—about $450 million in 2024—funds R\u0026amp;D and entry into speculative diagnostics like liquid biopsy and AI-driven assays, reducing dilution risk while backing strategic M\u0026amp;A.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3M tests\/year (2024)\u003c\/li\u003e\n\u003cli\u003e~25% operating margin (2024)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;30% US market share in molecular processing\u003c\/li\u003e\n\u003cli\u003e$450M free cash flow (2024)\u003c\/li\u003e\n\u003cli\u003eLow incremental CapEx to maintain throughput\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore assays drive $973M revenue, $450M FCF — funding R\u0026amp;D and \u0026gt;30% US share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash cows: BRACAnalysis CDx, Prolaris, EndoPredict, and core hereditary panels generated ~$973M revenue in FY2024–25, with combined gross margins 25–45% and free cash flow ~ $450M; they fund R\u0026amp;D ($50M BRACAnalysis contribution) and low incremental CapEx while sustaining payer coverage and \u0026gt;30% US processing share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25 Revenue\u003c\/th\u003e\n\u003cth\u003eMarket Share\u003c\/th\u003e\n\u003cth\u003eGross Margin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRACAnalysis CDx\u003c\/td\u003e\n\u003ctd\u003e$150M\u003c\/td\u003e\n\u003ctd\u003e~40% US\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProlaris\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003ctd\u003e30–35% US\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndoPredict\u003c\/td\u003e\n\u003ctd\u003e$110M\u003c\/td\u003e\n\u003ctd\u003e~35% global\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHereditary panels\u003c\/td\u003e\n\u003ctd\u003e$493M\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMyriad BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Myriad BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, presentation-ready document built for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748372197753,"sku":"myriad-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/myriad-bcg-matrix.png?v=1772207452","url":"https:\/\/matrixbcg.com\/products\/myriad-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}